Mabwell, an innovation-driven biopharmaceutical company, has the whole industrial chain of R&D, manufacturing, and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Now, Mabwell has dozens of drug candidates in different R&D stages based on a world-class and state-of-the-art R&D engine. We focus on the therapeutic areas of auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases, etc. Of these, 1 BLA has been filed, 8 products are in different stages of clinical study and 2 products have been approved for clinical trials initiation. We have also undertaken 2 national key R&D programs and several provincial and municipal level science and technological innovation projects. Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA. The large-scale manufacturing base located in Shanghai is under construction. The company completed Series A funding of 1.97 billion RMB in 2020 and submit IPO application to the SSE STAR Market as well. Our mission is "Explore Life, Benefit Health" and our vision is "Innovation, from ideas to reality".